Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etude de phase IV, milticentrique, randomisee, ouverte, comparant les reactions et la douleur aux sites d'injection apres administrartion sous-cutaneed' interferon beta-1b (Betaferon(RM)) ou interferon beta-1a (Rebif(RM)) pendant la periode de troi mois d'initiation de la therapie chez des patients atteints d'une forme recurrente/remittente de sclerose en plaques. AVANTAGE: Analyse comparative des reactions aux sites d'injection sur venues apres administration de betaferon 25 microg ou rebif 44 microg

Next Previous
X
Search
Trial Profile

Etude de phase IV, milticentrique, randomisee, ouverte, comparant les reactions et la douleur aux sites d'injection apres administrartion sous-cutaneed' interferon beta-1b (Betaferon(RM)) ou interferon beta-1a (Rebif(RM)) pendant la periode de troi mois d'initiation de la therapie chez des patients atteints d'une forme recurrente/remittente de sclerose en plaques. AVANTAGE: Analyse comparative des reactions aux sites d'injection sur venues apres administration de betaferon 25 microg ou rebif 44 microg

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1b (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms AVANTAGE
  • Sponsors Bayer HealthCare Pharmaceuticals

    • Most Recent Events

    • 12 Jan 2012 Company (Bayer Healthcare) added as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Actual end date changed from 1 Dec 2007 to 1 May 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top